WO2007109698A3 - Novel formulations - Google Patents

Novel formulations Download PDF

Info

Publication number
WO2007109698A3
WO2007109698A3 PCT/US2007/064462 US2007064462W WO2007109698A3 WO 2007109698 A3 WO2007109698 A3 WO 2007109698A3 US 2007064462 W US2007064462 W US 2007064462W WO 2007109698 A3 WO2007109698 A3 WO 2007109698A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
novel formulations
fpf
variability
therapy
Prior art date
Application number
PCT/US2007/064462
Other languages
French (fr)
Other versions
WO2007109698A2 (en
Inventor
John Capecchi
James Stefely
Trevor Riley
Original Assignee
Glaxo Group Ltd
3M Innovative Properties Co
John Capecchi
James Stefely
Trevor Riley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007109698(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP07758963A priority Critical patent/EP2012797A2/en
Priority to BRPI0708798-5A priority patent/BRPI0708798A2/en
Priority to AU2007226899A priority patent/AU2007226899A1/en
Priority to JP2009501708A priority patent/JP2009530419A/en
Priority to CA002646236A priority patent/CA2646236A1/en
Application filed by Glaxo Group Ltd, 3M Innovative Properties Co, John Capecchi, James Stefely, Trevor Riley filed Critical Glaxo Group Ltd
Priority to MX2008011967A priority patent/MX2008011967A/en
Priority to EA200801854A priority patent/EA200801854A1/en
Publication of WO2007109698A2 publication Critical patent/WO2007109698A2/en
Priority to IL193723A priority patent/IL193723A0/en
Priority to NO20083760A priority patent/NO20083760L/en
Publication of WO2007109698A3 publication Critical patent/WO2007109698A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel pharmaceutical aerosol formulations, processes for their preparation, their use in therapy, metered dose inhalers containing said formulations and the use of biocompatible polymers in reducing the variability in the content uniformity and/or in providing enhanced fine particle fraction (FPF) in said formulations.
PCT/US2007/064462 2006-03-22 2007-03-21 Novel formulations WO2007109698A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EA200801854A EA200801854A1 (en) 2006-03-22 2007-03-21 NEW COMPOSITIONS
BRPI0708798-5A BRPI0708798A2 (en) 2006-03-22 2007-03-21 aerosol pharmaceutical formulation, process for preparing an aerosol formulation, use of aerosol pharmaceutical formulation, method of treating or prophylaxis of a respiratory disorder, metered dose inhaler, and use of biocompatible polymer
AU2007226899A AU2007226899A1 (en) 2006-03-22 2007-03-21 Novel formulations
JP2009501708A JP2009530419A (en) 2006-03-22 2007-03-21 New formulation
CA002646236A CA2646236A1 (en) 2006-03-22 2007-03-21 Novel formulations
EP07758963A EP2012797A2 (en) 2006-03-22 2007-03-21 Novel formulations
MX2008011967A MX2008011967A (en) 2006-03-22 2007-03-21 Novel formulations.
IL193723A IL193723A0 (en) 2006-03-22 2008-08-27 Novel formulations
NO20083760A NO20083760L (en) 2006-03-22 2008-09-01 New formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22
US60/784,634 2006-03-22

Publications (2)

Publication Number Publication Date
WO2007109698A2 WO2007109698A2 (en) 2007-09-27
WO2007109698A3 true WO2007109698A3 (en) 2008-12-18

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/064462 WO2007109698A2 (en) 2006-03-22 2007-03-21 Novel formulations

Country Status (18)

Country Link
EP (1) EP2012797A2 (en)
JP (1) JP2009530419A (en)
KR (1) KR20080110854A (en)
CN (1) CN101415428A (en)
AR (1) AR060039A1 (en)
AU (1) AU2007226899A1 (en)
BR (1) BRPI0708798A2 (en)
CA (1) CA2646236A1 (en)
CR (1) CR10261A (en)
EA (1) EA200801854A1 (en)
IL (1) IL193723A0 (en)
MA (1) MA30328B1 (en)
MX (1) MX2008011967A (en)
NO (1) NO20083760L (en)
PE (1) PE20080124A1 (en)
TW (1) TW200803870A (en)
WO (1) WO2007109698A2 (en)
ZA (1) ZA200807682B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3578169T (en) * 2009-02-26 2024-07-29 Glaxo Group Ltd Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021229A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US20040028615A1 (en) * 2000-08-05 2004-02-12 Keith Biggadike 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021229A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US20040028615A1 (en) * 2000-08-05 2004-02-12 Keith Biggadike 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US20050130947A1 (en) * 2002-02-04 2005-06-16 Keith Biggadike Formulations for inhalation

Also Published As

Publication number Publication date
ZA200807682B (en) 2009-11-25
CA2646236A1 (en) 2007-09-27
PE20080124A1 (en) 2008-04-21
EA200801854A1 (en) 2009-04-28
EP2012797A2 (en) 2009-01-14
JP2009530419A (en) 2009-08-27
CR10261A (en) 2008-11-26
TW200803870A (en) 2008-01-16
WO2007109698A2 (en) 2007-09-27
NO20083760L (en) 2008-12-17
MA30328B1 (en) 2009-04-01
BRPI0708798A2 (en) 2011-06-14
IL193723A0 (en) 2009-08-03
AU2007226899A1 (en) 2007-09-27
CN101415428A (en) 2009-04-22
AR060039A1 (en) 2008-05-21
KR20080110854A (en) 2008-12-19
MX2008011967A (en) 2009-01-14

Similar Documents

Publication Publication Date Title
WO2007121913A3 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2005102431A3 (en) Aerosol delivery apparatus for pressure assisted breathing
IL178822A (en) 4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders
IL228952A0 (en) Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders
IL202840A (en) Substituted n-aryl pyridinones, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of fibrotic-mediated disorders and collagen-mediated disorders
IL183108A (en) Triazole compounds, pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating proliferation disorders
WO2008105773A3 (en) System for targeted delivery of therapeutic agents
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
MX346424B (en) Dry powder formulation comprising a phosphodiesterase inhibitor.
CA2558212A1 (en) Interferon-beta for anti-virus therapy for respiratory diseases
IL198314A (en) Quinuclidine derivatives of (hetero) arylcycloheptanecarboxylic acid, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for therapy
WO2007123945A3 (en) Mechanical single dose intrapulmonary drug delivery devices
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2006008517A3 (en) Use of dry powder compositions for pulmonary delivery
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
BR112014008609A2 (en) pharmaceutical composition, sealed container, metered dose inhaler, method for treating a patient suffering or likely to suffer from a respiratory disorder, and method for manufacturing a pharmaceutical composition
NZ701261A (en) Novel dosage form and formulation of abediterol
MY157186A (en) Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2012040228A3 (en) Aerosol composition for administering drugs
WO2005041921A3 (en) Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2005041922A3 (en) Composition
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2007109698A3 (en) Novel formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07758963

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 3473/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 570804

Country of ref document: NZ

Ref document number: 193723

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: CR2008-010261

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2007226899

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2646236

Country of ref document: CA

Ref document number: 200801854

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2009501708

Country of ref document: JP

Ref document number: 12008502106

Country of ref document: PH

Ref document number: 200780009835.1

Country of ref document: CN

Ref document number: MX/A/2008/011967

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008091557

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007226899

Country of ref document: AU

Date of ref document: 20070321

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 08102849

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2007758963

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087025825

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0708798

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080917